Evidence for an Important Role of Glucagon in the Regulation of Hepatic Glucose Production in Normal Man

JOHN E. LILJENQUIST, GARY L. MUELLER, ALAN D. CHERRINGTON, ULRICH KELLER, JEAN-LOUIS CHIASSON, JAMES M. PERRY, WILLIAM W. LACY, and DAVID RABINOWITZ

From the Departments of Medicine and Physiology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232

ABSTRACT To investigate the role of glucagon in regulating hepatic glucose production in man, selective glucagon deficiency was produced in four normal men by infusing somatostatin (0.9 mg/h) and regular pork insulin (150-μU/kg per min) for 2 h. Exogenous glucagon was infused to maintain euglycemia. Arterial plasma glucagon levels fell by greater than 50% whereas plasma insulin levels were maintained in the range of 10–14 μU/ml. In response to these hormonal changes, net splanchnic glucose production (NSGP) fell by 75% and remained suppressed for the duration of the study.

In contrast, when somatostatin alone was administered to normal men, resulting in combined insulin and glucagon deficiency (euglycemia again maintained), NSGP fell markedly but only transiently, reaching its nadir at 15 min. Thereafter, NSGP rose progressively, reaching the basal rate at 105 min.

These data indicate that the induction of selective glucagon deficiency in man (with basal insulin levels maintained) is associated with a marked and sustained fall in hepatic glucose production. We conclude, therefore, that basal glucagon plays an important role in the maintenance of basal hepatic glucose production in normal man.

INTRODUCTION

Whereas a major role for insulin in the regulation of hepatic glucose production in vivo is now well established (1–3), historically, glucagon has been ascribed only a minor role in the regulation of this process (4). Glucagon, though long known to be a potent glycogenolytic agent (5), was felt to be important in preventing hypoglycemia after a protein meal (4, 6, 7), but evidence that it regulated basal hepatic glucose production in man was not available.

Recently the availability of somatostatin (8) has focused new attention on glucagon and its role in regulating hepatic glucose production. By virtue of its ability to suppress endogenous insulin and glucagon secretion when administered systemically (9), somatostatin has provided a way to separate the role of glucagon from that of insulin in the regulation of this process.

Initial studies employing somatostatin in the baboon indicated that decreasing the circulating levels of insulin and glucagon resulted in a fall in the plasma glucose concentration (9). This fall has subsequently been shown in the dog to be secondary to a decline in hepatic glucose production (10, 11) specifically due to the lowering of circulating glucagon (11).
To date, no studies have been reported in man utilizing somatostatin to investigate the role of glucagon in regulating hepatic glucose production. We undertook the present study, therefore, to answer two questions: (a) what are the effects of inducing selective hypoglycaemia (with maintenance of basal insulin levels) on splanchnic glucose production in man? and (b) does the concomitant induction of insulin deficiency modify the effects of acute glucagonopenia on this same process? To answer these questions, somatostatin was infused with and without a replacement insulin infusion to normal men who had undergone hepatic vein catheterization.

METHODS

Eight healthy, nonobese men between the ages of 18 and 30 were studied. The mean body weight was 74.8 kg (range, 56.3–86.0 kg). Studies began between 12:00 noon and 2:00 p.m. after a 12–14-h fast.

The subjects were all placed on a 200-g carbohydrate diet for 3 days before study. In the 24 h before study, each subject received a high protein (150–200 g), high carbohydrate (300–350 g) diet. The protocol for this study was reviewed and approved by the Vanderbilt University Clinical Investigations Committee. The nature, purpose, and possible risks of the procedures were fully explained to each subject before obtaining his voluntary consent.

Hepatic venous and brachial arterial catheterization were performed as previously described (12). After a 30-min basal period, 0.9 mg/h somatostatin was infused intravenously for 2 h in both groups of four subjects. In the first group, 150 μU/kg per min regular pork insulin was infused concomitantly into a peripheral vein. In both groups, euglycaemia was maintained during somatostatin infusion by intravenous glucose administered at a variable rate according to the technique of Andres et al. (13). This was done to avoid any stimulatory effects of hypoglycaemia on hepatic glucose production. To determine hepatic blood flow, indocyanine green was infused throughout the study via a peripheral vein.

Cyclic somatostatin was kindly provided by Dr. Roger Guillemín, Chief, Neuroendocrinology Division, Salk Institute, La Jolla, Calif. For infusion, insulin and somatostatin were mixed in saline with human serum albumin (2 ml of 25% human serum albumin/100 ml of solution) to eliminate the binding of the hormones to glassware. Human serum albumin was similarly added to the indocyanine green infusion to increase its stability.

Plasma glucose was measured in a Beckman Glucose Analyzer (Beckman Instruments, Inc., Fullerton, Calif.). Plasma glucose was converted to whole blood glucose concentration (14) by the formula: whole blood glucose concentration = plasma glucose concentration (1–0.3 hematocrit). Immunoactive glucagon was assayed with the 30K antiserum of Aguilar-Parada et al. (15). Immunoactive insulin was assayed by the Sephadex-bound (Pharmacia Fine Chemicals, Inc., Piscataway, N. J.) antibody procedure (16). The plasma concentrations of indocyanine green were determined in a Beckman spectrophotometer at 510 nm and hepatic blood flow was calculated according to the method of Levey et al. (17). The statistical significance was determined by the Student’s or paired t test whenever applicable (18).

RESULTS

Infusion of somatostatin and insulin. In the first set of experiments, the infusion of somatostatin resulted in a sharp fall in the plasma glucagon level which remained suppressed at less than 50% of basal (Fig. 1). Plasma insulin levels, however, were maintained between 10 and 14 μU/ml by the insulin infusion. Thus, a state of selective glucagon deficiency was produced.

Table I displays estimated hepatic blood flow (EHBF) 1 and mean hepatic venous-arterial blood glu-

<p>| TABLE I |
| Mean EHBFL and HV-A Blood Glucose Differences during Infusion of Somatostatin and Regular Pork Insulin (150 μU/kg/min) in Normal Man (n = 4) |</p>
<table>
<thead>
<tr>
<th>Min</th>
<th>−30</th>
<th>−20</th>
<th>−10</th>
<th>0</th>
<th>15</th>
<th>30</th>
<th>45</th>
<th>60</th>
<th>75</th>
<th>90</th>
<th>105</th>
<th>120</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean EHBF, ml/min</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean</td>
<td>1,682</td>
<td>1,623</td>
<td>1,627</td>
<td>1,553</td>
<td>1,069</td>
<td>1,089</td>
<td>1,075</td>
<td>1,040</td>
<td>1,103</td>
<td>1,130</td>
<td>1,138</td>
<td>1,125</td>
</tr>
<tr>
<td>SE</td>
<td>149</td>
<td>135</td>
<td>126</td>
<td>210</td>
<td>223</td>
<td>149</td>
<td>141</td>
<td>162</td>
<td>177</td>
<td>206</td>
<td>157</td>
<td>189</td>
</tr>
<tr>
<td>Mean HV-A blood glucose difference, mg/dl</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean</td>
<td>9.7</td>
<td>10.1</td>
<td>9.2</td>
<td>10.8</td>
<td>4.5</td>
<td>3.9</td>
<td>2.6</td>
<td>3.0</td>
<td>3.7</td>
<td>4.6</td>
<td>3.7</td>
<td>4.3</td>
</tr>
<tr>
<td>SE</td>
<td>0.9</td>
<td>1.0</td>
<td>0.4</td>
<td>1.1</td>
<td>0.9</td>
<td>0.9</td>
<td>0.7</td>
<td>1.0</td>
<td>1.2</td>
<td>1.6</td>
<td>0.6</td>
<td>0.8</td>
</tr>
</tbody>
</table>

1 Abbreviations used in this paper: EHBFl, estimated hepatic blood flow; HV-A, hepatic venous-arterial; NSGP, net splanchnic glucose production.
cose differences before and during infusion of somatostatin and insulin. A significant fall in EHBF was observed. The hepatic venous-arterial (HV-A) blood glucose differences declined immediately after the somatostatin and insulin infusion was begun and remained suppressed throughout the entire study.

Fig. 2A shows that net splanchnic glucose production (NSGP) fell markedly during the administration of somatostatin and insulin and remained suppressed for the duration of the study. Despite this fall in NSGP, euglycemia was maintained (Fig. 2B) by the infusion of glucose at the mean rate shown in Fig. 2C.

**Infusion of somatostatin alone.** The administration of somatostatin alone resulted in marked suppression of circulating plasma insulin and glucagon concentrations (Fig. 3). Plasma insulin levels declined from 9.2 ± 1.9 to 1.8 ± 1.2 μU/ml whereas the circulating glucagon concentrations fell by more than 50% as in the previous protocol. The levels of both hormones remained suppressed.

![Figure 2](image)

**FIGURE 2** Effects of intravenous somatostatin (0.9 mg/h) and regular pork insulin on (A) net splanchnic glucose production and, (B) arterial plasma glucose concentration. (C) Depicts the rate of exogenous glucose infusion necessary to prevent hypoglycemia.

The administration of somatostatin alone resulted in an immediate fall in EHBF which persisted for the duration of the study (Table II). HV-A blood glucose differences declined sharply by 15 min, remained significantly suppressed at 30 min, but then gradually returned to control levels by 90 min.

The administration of somatostatin alone resulted in a rapid and highly significant, 74%, decline in NSGP (Fig. 4A) which reached its nadir at 15 min; thereafter, NSGP rose progressively. By 105 min, despite continuing suppression of insulin and glucagon secretion, NSGP had returned to normal. Euglycemia (Fig. 4B) was maintained for the initial 60 min of the somatostatin infusion period by the concomitant infusion of glucose at the mean rate shown in Fig. 4C. As NSGP returned towards basal, the mean arterial glucose concentration rose (Fig. 4B), necessitating a diminution in the amount of glucose infused (Fig. 4C). In three of four subjects, the glucose infusion was completely stopped between times 50 and 70 min of the study but modest hyperglycemia nevertheless developed in all three subjects.

**DISCUSSION**

The intravenous infusion of somatostatin plus regular pork insulin at the rate of 150 μU/kg per min resulted in a state of selective glucagon deficiency. Circulating insulin levels were maintained in the range of 10–14 μU/ml and glucagon levels fell by greater than 50%. Under these conditions, splanchnic glucose output declined by 75% and remained suppressed until the end of the 2-h study. These data indicate that the maintenance of basal hepatic glucose production in normal man is highly dependent on circulating glucagon and, furthermore, suggests that the lowering of circulating glucagon does not result in an evanescent but rather a sustained fall in hepatic glucose production. Both of these conclusions are further substantiated by recent results from our laboratory which showed that in dogs made glucagon deficient by con-
comitant infusion of insulin and somatostatin, glucose production fell and remained below normal over a 4.5-h period despite persisting hypoglycemia.\(^2\)

The infusion of somatostatin alone resulted in combined insulin and glucagon deficiency. Under these conditions, NSGP fell markedly but only transiently and returned to normal within 2 h. This is in contrast to the previous protocol in which maintenance of arterial insulin levels between 10 and 14 \(\mu\)U/ml resulted in a persistent decrease in NSGP. These data indicate that when glucagon is deficient, hepatic glucose production is profoundly sensitive to circulating levels of insulin which are approximately 50% of those normally found in the portal vein (19).

The administration of somatostatin with or without concomitant insulin infusion resulted in significant decrements in EHBf of 34 and 25%, respectively (Tables I and II). However, the mean HV-A blood glucose differences in these two protocols decreased even more dramatically (74 and 72%, respectively). Because the calculation of NSGP is determined by both of these parameters, the fall in glucose production was primarily attributable to the decline in HV-A blood glucose difference. The rebound in the HV-A blood glucose difference, (3.5-fold over the minimum value), which occurred in the group receiving somatostatin alone also exceeded the concomitant statistically insignificant 13% rebound in blood flow which gradually occurred and was, therefore, again the primary determinant of the modification in NSGP.

It seems unlikely for two reasons that the decline in hepatic blood flow per se, rather than the changes in pancreatic hormone levels, could have produced the alterations noted in NSGP. First, we have performed similar studies using dogs in which somatostatin administration also resulted in a significant decrease in hepatic glucose production but did so in the total absence of any change in splanchic blood flow (11). Secondly, a drop in hepatic blood flow of this magnitude to have any effect on NSGP, it would be expected to increase rather than decrease it as suggested by studies of hepatic glucose production during periods of decreased hepatic blood flow (20).

The administration of somatostatin to baboons, dogs, and men has resulted in suppression of circulating insulin and glucagon levels and in the acute development of hypoglycemia secondary to a decrease in hepatic glucose production (9–11). The present study demonstrates, however, that the acute induction of

![Figure 4](image)

**Figure 4** Effects of intravenous somatostatin (0.9 mg/h) on (A) net splanchic glucose production and (B) arterial plasma glucose concentration. (C) Depicts the rate of exogenous glucose infusion necessary to prevent hypoglycemia.

---


### Table II

<table>
<thead>
<tr>
<th>Mean EHBf and HV-A Blood Glucose Differences during Infusion of Somatostatin in Normal Man (n = 4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Min</td>
</tr>
<tr>
<td>Mean EHBf, ml/min</td>
</tr>
<tr>
<td>SE</td>
</tr>
<tr>
<td>Mean HV-A blood glucose difference, mg/dl</td>
</tr>
<tr>
<td>SE</td>
</tr>
</tbody>
</table>

---

Liljenquist et al.
combined insulin and glucagon deficiency results in only a transient decrease in NSGP which effects only transient hypoglycemia. Indeed, a modest hyperglycemia of 117 mg/dl developed during the 2nd h of the study. Similar results have been reported by Altszuler et al. (10) who noted that glucose production had returned to normal by 90 min in a third of their dogs receiving somatostatin. Thus, acute induction of combined insulin and glucagon deficiency is not associated with continuing suppression of glucose production.

The cause of the return of glucose production to normal despite continuing deficiency of insulin and glucagon is unknown. As euglycemia was maintained in the present study during somatostatin administration, the rise in NSGP towards the basal rate cannot be attributed to the counter-regulatory responses attendant upon hypoglycemia. In unpublished observations from human studies in our laboratory, we have noted that the inhibitory effects on NSGP of small increments in circulating insulin persist for approximately 30 min after cessation of the insulin infusion. The rise in NSGP towards basal appears to begin 15–30 min after initiation of somatostatin infusion (Fig. 4A) and may simply reflect the attenuation of the effects of basal insulin on the liver. Conversely, by infusing small amounts of insulin to maintain circulating arterial insulin levels in the range of 10–14 μU/ml, far below normal portal venous insulin levels (19), NSGP remains suppressed and does not return to basal during somatostatin infusion. Another factor which may be responsible for this return of NSGP to normal is the residual immunoreactive glucagon which continues to circulate during somatostatin administration. Although it has been shown that this material probably does not represent pancreatic glucagon (21), nonetheless it is possible that it has some glycogenolytic activity which might be more prominent during states of insulinopenia.

Two sets of factors may have influenced the magnitude of the observed effects in this study. On the one hand, mean plasma glucagon levels were somewhat higher than we have observed in previous studies (12). These values were verified by independent assay in the laboratory of Dr. A. H. Rubenstein, University of Chicago, Pritzker School of Medicine. It is possible that the higher glucagon levels reflect the enrichment in protein of the subjects' diet on the day preceding the test. Basal NSGP and other metabolic indices, however, (e.g. individual amino acids, free fatty acids) were similar to those in previous studies. Nevertheless, in the presence of the higher basal glucagon levels, our studies may overestimate the role of glucagon in the control of splanchnic glucose production. On the other hand, about 50% of basal glucagon immunoreactivity is not suppressed during somatostatin infusion. Should this material have any glycogenolytic or gluconeogenic activity, its continuing presence would lead us to underestimate the overall role of glucagon in regulating hepatic glucose production.

The interpretation of the data in this study is contingent upon the assumption that the extrapancreatic actions of somatostatin were not involved in the mediation of the biological responses observed. Somatostatin does not have direct effects on glucose flux in fat, muscle, or liver cells studies in vitro (22). Somatostatin, however, does inhibit the release of a variety of other hormones including growth hormone (8). Although this could have influenced the results of our study, it does not seem likely, because Gerich et al. (23) replaced growth hormone during somatostatin administration and noted no effect on the plasma glucose concentration. More definitive evidence emerges from our studies in the dog in which intraportal insulin and glucagon replacement during somatostatin administration results in maintenance of NSGP at basal rates (11). Our data, however, do not exclude a role for growth hormone in modifying the sensitivity of the liver to insulin.

The present study, therefore, presents data which indicate (a) that the induction of selective glucagon deficiency in man (with basal insulin levels maintained) is associated with a marked and sustained fall in hepatic glucose production, suggesting that basal glucagon plays an important role in the maintenance of hepatic glucose production in normal man; (b) that during periods of glucagon deficiency, glucose output by the liver is extremely sensitive to low levels of circulating insulin; and (c) that normal rates of hepatic glucose production are possible during glucagonopenia providing insulin is also deficient.

ACKNOWLEDGMENTS

The authors would like to acknowledge the excellent technical skills of Jill Hutton, Barbara Santoro, Phillip Williams, Patti Primm, and Leda Marshall. We are most grateful for the excellent secretarial skills of Lissa Hancock and Joyce Dawson.

This investigation was supported by U. S. Public Health Service grants AM-18243 and AM-19587, and General Clinical Research Center RR95, and the Vanderbilt University Diabetes-Endocrinology Center AM 17026.

Gary L. Mueller is a Major, U. S. Air Force-Medical Corps. The views or opinions expressed or implied are the author's and do not represent those of the U. S. Air Force or any agency of the U. S. Government.

REFERENCES


---


